Lilly Files 6 Lawsuits Against Retatrutide Sellers (August 12, 2026)

The main retatrutide lawsuit news came on August 12, 2026, when Eli Lilly announced 6 new lawsuits against US sellers of retatrutide and referred more than 200 people and companies to regulators and law enforcement. Lilly said no medicine containing retatrutide has been approved for human use by any regulator in the world, and that it can't be sold to consumers. The primary source is Lilly's August 12 release.

This page records what Lilly announced and what has been verified since. The legal position for buyers is on the is retatrutide legal page.

What Lilly filed on August 12

Lilly described the 6 defendants as compounding pharmacies, medical spas and online sellers. The cases sit in four federal districts across two states: one in the Northern District of California, two in the Western District of Texas, one in the Eastern District of Texas and two in the Southern District of Texas. We don't name the sellers here.

The release went wider than the courtroom. Lilly said it had referred more than 200 people and companies to the FDA, the Justice Department, state attorneys general, law enforcement and licensing boards. It also said it had reported more than 14,000 websites, ads, posts and listings marketing retatrutide in more than 100 countries, and it called on online platforms, payment companies and regulators to shut the market down.

The retatrutide lawsuit push next to the FDA's letters

Lilly's suits came in the same months as FDA action against sellers. The dated record from the primary sources:

The FDA's page on unapproved GLP-1 drugs adds that it has warned telehealth companies marketing retatrutide, distributors selling the ingredient to compounders, and outsourcing facilities repackaging it. Lilly's counterfeit page says federal prosecutors in Florida filed criminal proceedings against someone selling illicit retatrutide that turned out to contain a different active ingredient.

What it means if you're buying

The suits are aimed at sellers. For a buyer, the practical point is the one Lilly keeps repeating: anything sold as retatrutide isn't Lilly's product, and nobody outside the trials can tell you what's in it. Lilly's October 28 release says it plainly in its FAQ: "Anyone purporting to sell retatrutide to consumers is breaking the law."

Our read: lawsuits take listings down. They do nothing about what's in the vials still on sale. If you're reading about retatrutide for sale, the lab result in the TGA's September test matters more to your safety than any lawsuit.

What we couldn't verify

Several October reports went further than Lilly's own releases. Law firm and press reports describe 5 more lawsuits filed on October 8, 2026, and settlements or dismissals in some of the August cases. We found no Lilly release about either, and the complaints and dismissals weren't in the public court archive we checked, so we haven't treated them as fact. We'll add them when the court records or a Lilly statement confirm them.

How to report a seller

Lilly asks people to report illegal retatrutide products to regulators, law enforcement and the Lilly Answers Center at 1-800-LillyRx. Lilly Canada asks Canadians to report them to Health Canada and local police, and its Customer Response Centre is on 1-888-545-5972. The safety alerts page logs the regulator actions as they come out, and Eli Lilly and retatrutide covers the company's program.